Company: VCYT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001384101-25-000014
Chunk: 165

Company: VERACYTE, INC.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 165
---
Current liabilities:Accounts payable$8,634 $12,943 Accrued liabilities43,826 38,427 Current portion of deferred revenue1,673 2,008 Current portion of acquisition-related contingent consideration16,981 2,657 Current portion of operating lease liabilities7,500 5,105 Current portion of other liabilities19 101 Total current liabilities78,633 61,241 Deferred tax liability1,227 734 Acquisition-related contingent consideration, net of current portion561 518 Operating lease liabilities, net of current portion43,237 7,525 Other liabilities411 786 Total liabilities124,069 70,804 Commitments and contingenciesStockholders' equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and 2023— — Common stock, $0.001 par value; 125,000,000 shares authorized, 77,772,678 and 73,264,738 shares issued and outstanding as of December 31, 2024 and 2023, respectively78 73 Additional paid-in capital1,655,961 1,536,168 Accumulated deficit(443,983)(468,121)Accumulated other comprehensive loss(36,090)(24,018)Total stockholders' equity1,175,966 1,044,102 Total liabilities and stockholders' equity$1,300,035 $1,114,906    

The accompanying notes are an integral part of these consolidated financial statements.

84

VERACYTE, INC.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

 Year Ended December 31, 202420232022Revenue:Testing revenue$418,961 $326,542 $250,544 Product revenue13,650 15,588 12,632 Biopharmaceutical and other revenue13,153 18,921 33,360 Total revenue445,764 361,051 296,536 Cost of revenue:Cost of testing revenue114,573 88,913 75,317 Cost of product revenue9,110 8,666 7,820 Cost of biopharmaceutical and other revenue12,384 15,324 18,445 Intangible asset amortization